DZY-3, (camptothecin), which inhibits DNA replication in proliferating tumor cells, has been used as an antitumor drug for many years, and this study was able to propose a new mechanism for its antitumor action, by demonstrating that it inhibits FOXM1. Here, FOXM1 is linked to neoplasm.